Bristol-Myers Squibb Co (BMY) is now in the Undervalued zone, suggesting that its current forward PS ratio of 2.40 is considered Undervalued compared with the five-year average of 11.40. The fair price of Bristol-Myers Squibb Co (BMY) is between 68.83 to 91.16 according to relative valuation method. Compared to the current price of 62.37 USD , Bristol-Myers Squibb Co By Undervalued By 9.39%.

Relative Value

Fair Zone

68.83-91.16

Current Price：62.37

9.39%

Undervalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Bristol-Myers Squibb Co (BMY) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Bristol-Myers Squibb Co (BMY) has a current Price-to-Book (P/B) ratio of 5.87. Compared to its 3-year average P/B ratio of 5.15, the current P/B ratio is approximately 13.98% higher. Relative to its 5-year average P/B ratio of 4.81, the current P/B ratio is about 22.08% higher. Bristol-Myers Squibb Co (BMY) has a Forward Free Cash Flow (FCF) yield of approximately 14.06%. Compared to its 3-year average FCF yield of 12.08%, the current FCF yield is approximately 16.44% lower. Relative to its 5-year average FCF yield of 10.86%, the current FCF yield is about 29.52% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for BMY competitors is 3.90, providing a benchmark for relative valuation. Bristol-Myers Squibb Co Corp (BMY.N) exhibits a P/S ratio of 2.40, which is -38.44% above the industry average. Given its robust revenue growth of 1.30%, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of BMY increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of BMY in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is BMY currently overvalued or undervalued?

What is Bristol-Myers Squibb Co (BMY) fair value?

BMY's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Bristol-Myers Squibb Co (BMY) is between 68.83 to 91.16 according to relative valuation method.

How does BMY's valuation metrics compare to the industry average?

The average P/S ratio for BMY's competitors is 3.90, providing a benchmark for relative valuation. Bristol-Myers Squibb Co Corp (BMY) exhibits a P/S ratio of 2.40, which is -38.44% above the industry average. Given its robust revenue growth of 1.30%, this premium appears unsustainable.

What is the current P/B ratio for Bristol-Myers Squibb Co (BMY) as of Mar 02 2026?

As of Mar 02 2026, Bristol-Myers Squibb Co (BMY) has a P/B ratio of 5.87. This indicates that the market values BMY at 5.87 times its book value.

What is the current FCF Yield for Bristol-Myers Squibb Co (BMY) as of Mar 02 2026?

As of Mar 02 2026, Bristol-Myers Squibb Co (BMY) has a FCF Yield of 14.06%. This means that for every dollar of Bristol-Myers Squibb Co's market capitalization, the company generates 14.06 cents in free cash flow.

What is the current Forward P/E ratio for Bristol-Myers Squibb Co (BMY) as of Mar 02 2026?

As of Mar 02 2026, Bristol-Myers Squibb Co (BMY) has a Forward P/E ratio of 8.65. This means the market is willing to pay $8.65 for every dollar of Bristol-Myers Squibb Co's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Bristol-Myers Squibb Co (BMY) as of Mar 02 2026?

As of Mar 02 2026, Bristol-Myers Squibb Co (BMY) has a Forward P/S ratio of 2.40. This means the market is valuing BMY at $2.40 for every dollar of expected revenue over the next 12 months.

BMY Valuation